Of the five, two patients had elevated expression of immune markers in baseline biopsies; another three had >10% TIM-3-positive staining, including one patient with NSCLC who received prior PD-1 therapy (88). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.